数字减影血管造影在恶性输尿管梗阻治疗中的应用

doi:10.19558/j.cnki.10-1020/r.2019.03.003

摘要
图/表
参考文献
相关文章 (6)

全文: PDF (1466 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要目的回顾性分析无法耐受逆行输尿管支架置入或操作失败的恶性输尿管梗阻患者的临床资料,比较数字减影血管造影（DSA）引导下顺行输尿管支架置入与经皮肾造瘘治疗的临床疗效。方法收集2014月5月–2018年5月辽宁省肿瘤医院收治的逆行膀胱镜或输尿管镜下输尿管支架置入失败的恶性输尿管梗阻的病例。分别采用DSA引导下经皮顺行输尿管支架置入术（输尿管支架组,32例）与经皮肾造瘘术（造瘘组,39例）,统计两组病例血清肌酐指标、术中置管成功率、术后并发症等资料;并进行6个月随访,比较两组肾皮质厚度、血清肌酐值、导管堵塞率、导管更换成功率。结果两患者均未观察到与操作相关的并发症导致死亡的病例。输尿管支架组中5例患者由于梗阻严重导致导丝未能通过梗阻段,转行肾造瘘,成功率84.3%;造瘘组成功率100%。梗阻伴肾功能不全的病例（42例）中,术后1周血清肌酐水平均较术前有明显改善（P<0.05）。术后随访1个月,输尿管支架组及造瘘组肾皮质厚度较同组术前明显增加（P<0.05）;随访3个月,输尿管支架组导管堵塞率为11.6%,高于造瘘组的0%（P<0.05）;随访6个月,输尿管支架组导管更换成功率97.7%,高于造瘘组的85.7%（P<0.05）。结论 DSA引导下经皮顺行输尿管支架置入与经皮肾造瘘在治疗恶性输尿管梗阻中均安全、有效,可作为膀胱镜或输尿管镜下逆行输尿管支架置入失败的补充治疗方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郑文恒
	于韬
	罗娅红
	曾宇
	王颖
	善广夷
	李刚
	王凯

关键词 ：恶性输尿管梗阻, 经皮肾穿刺造瘘术, 输尿管支架, 肾盂积水, 肾功能不全

Abstract：Objective: To compare the clinical efficacy of anterograde ureteral stent placement vs. percutaneous nephrostomy in the treatment of ureteral obstruction caused by failure of retrograde ureteral stent placement under cystoscope or ureteroscope.Methods: Malignant ureteral obstruction cases admitted to Liaoning Cancer Hospital from May 2014 to May 2018 were collected. All cases failed to insert ureteral stent under retrograde cystoscope or ureteroscope. The patients were divided into ureteral stent group (32 cases) and fistula group (39 cases). The data of serum creatinine index, success rate of catheterization and complications were collected before and after operation. The renal cortex thickness, serum creatinine value, catheter blockage rate and success rate of catheter replacement were compared between the two groups after 6 months of follow-up. Results: No operative complications resulted in deaths in 71 patients. Among them, 5 patients in ureteral stent group were converted to nephrostomy because of the failure of guide wire opening during operation; the power of ureterostomy was 100%, higher than that of ureteral stent (84.3%, P<0.05); in 42 patients with obstruction and renal insufficiency, the serum creatinine levels in ureteral stent group and ureterostomy group were significantly reduced one week after operation (P<0.05). During the postoperative follow-up period of 1 month, the thickness of renal cortex in both groups was significantly increased as compared with that before operation (P<0.05). During the postoperative follow-up period of 3 months, the catheter blockage rate in the ureteral stent group was 11.6%, significantly higher than that in the nephrostomy group (0, P<0.05). The catheter replacement success rate in the ureteral stent group was 97.7%, and it was 85.7% in the nephrostomy group . Conclusions: Percutaneous anterograde ureteral stent placement and percutaneous nephrostomy are both safe and effective in the clinical application of alleviating malignant urinary tract obstruction, and can be used as a supplementary treatment for the failure of retrograde ureteral stent placement under cystoscopy or ureteroscopy.

Key words： malignant ureteral obstruction percutaneous nephrostomy ureteral stenting hydronephrosis renal insufficiency

收稿日期: 2019-02-11

ZTFLH:

R693

通讯作者: 于韬,yutao@cancerhosp-Ln-cmu.com

引用本文:

郑文恒, 于韬, 罗娅红, 曾宇, 王颖, 善广夷, 李刚, 王凯. 数字减影血管造影在恶性输尿管梗阻治疗中的应用[J]. 微创泌尿外科杂志, 2019, 8(3): 153-158.
ZHENG Wenheng, YU Tao, LUO Yahong, ZENG Yu, WANG Ying, SHAN Guangyi, LI Gang, WANG Kai. A comparative study of DSA-guided percutaneous antegrade ureteral stent placement vs. percutaneous nephrostomy in malignant ureteral tract obstruction. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2019, 8(3): 153-158.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1501.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2019/V8/I3/153

[1] ISHIOKA J, KAGEYAMA Y, INOUE M, et al.Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: Analysis of 140 cases. J Urol, 2008,180(2):618-621.
[2] WONG LM, CLEEVE LK, MILNER AD, et al.Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol, 2007,178(1):178-183.
[3] WILSON JR, URWIN GH, STOWER MJ.The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl, 2005,87(1):21-24.
[4] WANG JY, ZHANG HL, ZHU Y, et al.Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. Oncol Lett, 2016,11(1):879-883.
[5] KIM SH, PARK B, JOO J, et al.Retrograde pyelography predicts retrograde ureteral stenting failure and reduces unnecessary stenting trials in patients with advanced non-urological malignant ureteral obstruction. PLoS One, 2017,12(9):e0184965.
[6] FIUK J, BAO Y, CALLEARY JG, et al.The use of internal stents in chronic ureteral obstruction. J Urol, 2015,193(4):1092-1100.
[7] PUCHERIL D, DALELA D, SAMMON J, et al.The influence of physician recommendation on prostate-specific antigen screening. Urol Oncol, 2015,33(10):424.
[8] AL-AOWN A, KYRIAZIS I, KALLIDONIS P, et al.Ureteral stents: new ideas, new designs. Ther Adv Urol, 2010,2(2):85-92.
[9] 唐建辉,张军.双J管逆行置入术与经皮肾造瘘术在恶性肿瘤致输尿管狭窄治疗中的对比研究.中国医药指南,2012,10(35):160.
[10] 胡鸿涛,黎海亮,郭晨阳,等.DSA引导下顺行加逆行法双J管置入治疗妇科恶性肿瘤所致严重输尿管狭窄的可行性和安全性.中华放射学杂志,2015,49(4):315-316.
[11] KASKARELIS IS, PAPADAKI MG, MALLIARAKI NE.Complications of percutaneous nephrostomy,percutaneous insertion of ureteral endoprosthesis, and replacement procedures. Cardiovasc Intervent Radiol, 2001,24(4):224-228.
[12] AHMAD I, PANSOTA MS, TARIQ MA, et al.Comparison between double J (DJ) ureteral stenting and percutaneous nephrostomy (PCN) in obstructive uropathy. Pak J Med Sci, 2013,29(3):725-729.
[13] OLIVERA ST, GJULSEN S, KATICA Z.Obstructive nephropathy as a result of malignant neoplasms: a single centre experience. BANTAO J, 2010,8(2):71-74.
[14] ARSHAD M, SHAH SS, ABBASI MH.Applications and complications of polyurethane stenting in urology. J Ayub Med Coll Abbottabad, 2006,18(2):69-72.
[15] GANATRA AM, LOUGHLIN KR.The management of malignant ureteral obstruction treated with ureteral stents. J Urol, 2005,174(6):2125-2128.
[16] KIM JW, HONG B, SHIN JH, et al.A prospective randomized comparison of a covered metallic ureteral stent and a Double-J stent for malignant ureteral obstruction. Korean J Radiol, 2018,19(4):606-612.
[17] MONSKY WL, MOLLOY C, JIN B, et al.Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Intervent Radiol, 2013,36(5):1355-1363.
[18] SHEKARRIZ B, SHEKARRIZ H, UPADHYAY J, et al.Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer, 1999,85(4):998-1003.
[19] NEW F, DEVERILL S, SOMANI BK.Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature. Cent European J Urol, 2018,71(4):404-409.
[20] JALBANI MH, DEENARI RA, DHOLIA KR, et al.Role of percutaneous nephrostomy (PCN) in malignant ureteral obstruction. J Pak Med Assoc, 2010,60(4):280-283.